These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 14727239)

  • 1. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
    Thorstad WL; Haughey B; Chao KS
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
    Haddad R; Wirth L; Costello R; Weeks L; Posner M
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):84-8. PubMed ID: 14727246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
    Anné PR; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative radiation therapy (IORT) in head and neck cancer: A systematic review.
    Kyrgias G; Hajiioannou J; Tolia M; Kouloulias V; Lachanas V; Skoulakis C; Skarlatos I; Rapidis A; Bizakis I
    Medicine (Baltimore); 2016 Dec; 95(50):e5035. PubMed ID: 27977569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative radiation therapy in the multimodality approach to upper aerodigestive tract cancer.
    Carter YM; Jablons DM; DuBois JB; Thomas CR
    Surg Oncol Clin N Am; 2003 Oct; 12(4):1043-63. PubMed ID: 14989132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
    Chao KS; Ozyigit G; Thorsdad WL
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):202-4. PubMed ID: 11355589
    [No Abstract]   [Full Text] [Related]  

  • 19. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.